{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"24.1","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"description":"Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible.","dispersionType":"Full Range","groups":[{"description":"All patients who received at least one dose of pralatrexate and had an eligible PTCL histopathological subtype confirmed by central pathology review.","id":"OG000","title":"Evaluable Population"}],"paramType":"MEDIAN","populationDescription":"Analysis was per protocol, based on the number of patients (pts) who had an event (death or censoring) at the time of data cut-off.","reportingStatus":"POSTED","timeFrame":"Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.","title":"Overall Survival Per Independent Central Review","type":"SECONDARY","unitOfMeasure":"Months"}